Comerica Bank Sells 11,556 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Comerica Bank decreased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMATFree Report) by 6.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 158,479 shares of the medical instruments supplier’s stock after selling 11,556 shares during the period. Comerica Bank owned approximately 0.71% of LeMaitre Vascular worth $8,634,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Legal & General Group Plc grew its holdings in shares of LeMaitre Vascular by 0.4% during the 2nd quarter. Legal & General Group Plc now owns 45,769 shares of the medical instruments supplier’s stock valued at $2,084,000 after purchasing an additional 200 shares during the last quarter. Cerity Partners LLC purchased a new stake in LeMaitre Vascular during the 1st quarter valued at $380,000. Sei Investments Co. increased its position in shares of LeMaitre Vascular by 0.8% in the fourth quarter. Sei Investments Co. now owns 30,471 shares of the medical instruments supplier’s stock valued at $1,402,000 after acquiring an additional 248 shares during the period. FMR LLC grew its stake in shares of LeMaitre Vascular by 111.7% in the first quarter. FMR LLC now owns 633 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 334 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its position in shares of LeMaitre Vascular by 5.7% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 6,256 shares of the medical instruments supplier’s stock worth $421,000 after buying an additional 339 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 1.0 %

NASDAQ LMAT opened at $66.84 on Friday. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $74.64. The company’s 50-day moving average price is $61.28 and its 200-day moving average price is $56.31. The stock has a market cap of $1.49 billion, a PE ratio of 49.88, a PEG ratio of 2.87 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.02. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The company had revenue of $48.90 million for the quarter, compared to analyst estimates of $49.01 million. During the same period last year, the company posted $0.25 earnings per share. LeMaitre Vascular’s revenue was up 19.3% compared to the same quarter last year. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.66 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Thursday, March 14th will be issued a $0.16 dividend. The ex-dividend date is Wednesday, March 13th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.96%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 47.76%.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of analyst reports. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday. Barrington Research increased their price target on LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. Finally, KeyCorp started coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They set a “sector weight” rating for the company. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $68.20.

Get Our Latest Stock Analysis on LMAT

Insider Buying and Selling

In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares of the company’s stock, valued at $358,357.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John A. Roush sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the transaction, the director now owns 2,278 shares in the company, valued at $157,182. The disclosure for this sale can be found here. Insiders sold 114,036 shares of company stock worth $7,873,749 in the last 90 days. Insiders own 12.40% of the company’s stock.

LeMaitre Vascular Profile

(Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Featured Articles

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMATFree Report).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.